About: Lerdelimumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2. It was being developed to reduce scarring after glaucoma drainage surgery. Development was stopped in late 2005 after unsuccessful trial results for that condition.

Property Value
dbo:abstract
  • لردليموماب جسم مضاد وحيد النسيلة بشري ودواء مثبط للمناعة كان من المفترض تسميته تجارياً ترابيو (Trabio) ليستخدم في جراحة الزرق لكن التجارب السريرية ألغيت عام 2005 بعد نتائج غير ناجحة. (ar)
  • Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2. It was being developed to reduce scarring after glaucoma drainage surgery. Development was stopped in late 2005 after unsuccessful trial results for that condition. (en)
  • Il lerdelimumab o CAT-152, nome commerciale Trabio, è un anticorpo monoclonale di tipo umano, ad attività immunosoppressiva che viene utilizzato per ridurre le cicatrici post-chirurgia del glaucoma. Il farmaco agisce sull'antigene fattore di crescita trasformante beta 2. (it)
dbo:casNumber
  • 285985-06-0
dbo:fdaUniiCode
  • GX1FEU3QSM
dbo:wikiPageID
  • 9132535 (xsd:integer)
dbo:wikiPageLength
  • 2011 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1029723956 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • none (en)
dbp:casNumber
  • 285985 (xsd:integer)
dbp:chemspiderid
  • none (en)
dbp:legalStatus
  • Development discontinued (en)
dbp:mabType
  • mab (en)
dbp:source
  • u (en)
dbp:target
dbp:type
  • mab (en)
dbp:unii
  • GX1FEU3QSM (en)
dbp:verifiedfields
  • changed (en)
dbp:verifiedrevid
  • 458270397 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • لردليموماب جسم مضاد وحيد النسيلة بشري ودواء مثبط للمناعة كان من المفترض تسميته تجارياً ترابيو (Trabio) ليستخدم في جراحة الزرق لكن التجارب السريرية ألغيت عام 2005 بعد نتائج غير ناجحة. (ar)
  • Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2. It was being developed to reduce scarring after glaucoma drainage surgery. Development was stopped in late 2005 after unsuccessful trial results for that condition. (en)
  • Il lerdelimumab o CAT-152, nome commerciale Trabio, è un anticorpo monoclonale di tipo umano, ad attività immunosoppressiva che viene utilizzato per ridurre le cicatrici post-chirurgia del glaucoma. Il farmaco agisce sull'antigene fattore di crescita trasformante beta 2. (it)
rdfs:label
  • لردليموماب (ar)
  • Lerdelimumab (it)
  • Lerdelimumab (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License